A detailed history of Rhenman & Partners Asset Management Ab transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 238,500 shares of GILD stock, worth $21.2 Million. This represents 1.62% of its overall portfolio holdings.

Number of Shares
238,500
Previous 127,000 87.8%
Holding current value
$21.2 Million
Previous $9.3 Million 75.91%
% of portfolio
1.62%
Previous 0.91%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $7.04 Million - $8.13 Million
111,500 Added 87.8%
238,500 $16.4 Million
Q1 2024

May 14, 2024

SELL
$71.58 - $87.29 $9.45 Million - $11.5 Million
-132,000 Reduced 50.97%
127,000 $9.3 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $1.83 Million - $2.08 Million
25,000 Added 10.68%
259,000 $21 Million
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $12.5 Million - $13.7 Million
169,500 Added 262.79%
234,000 $17.5 Million
Q3 2023

Nov 09, 2023

SELL
$73.94 - $80.67 $12.5 Million - $13.7 Million
-169,500 Reduced 72.44%
64,500 $4.83 Million
Q2 2023

Aug 11, 2023

SELL
$76.01 - $86.7 $1.9 Million - $2.17 Million
-25,000 Reduced 9.65%
234,000 $18 Million
Q1 2023

May 11, 2023

SELL
$77.31 - $88.08 $850,410 - $968,880
-11,000 Reduced 4.07%
259,000 $21.5 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $4.17 Million - $4.76 Million
70,000 Added 35.0%
270,000 $21.2 Million
Q2 2022

Aug 12, 2022

BUY
$57.72 - $65.01 $1.73 Million - $1.95 Million
30,000 Added 17.65%
200,000 $12.4 Million
Q1 2022

May 13, 2022

SELL
$57.92 - $72.58 $6.08 Million - $7.62 Million
-105,000 Reduced 38.18%
170,000 $10.1 Million
Q4 2021

Feb 11, 2022

SELL
$64.88 - $73.64 $1.62 Million - $1.84 Million
-25,000 Reduced 8.33%
275,000 $20.2 Million
Q2 2021

Aug 13, 2021

SELL
$63.47 - $69.35 $3.17 Million - $3.47 Million
-50,000 Reduced 14.29%
300,000 $20.7 Million
Q1 2021

May 14, 2021

SELL
$60.0 - $68.46 $2.1 Million - $2.4 Million
-35,000 Reduced 9.09%
350,000 $22.6 Million
Q4 2020

Jan 19, 2021

BUY
$56.65 - $64.55 $5.38 Million - $6.13 Million
95,000 Added 32.76%
385,000 $22.4 Million
Q3 2020

Oct 13, 2020

BUY
$62.1 - $78.08 $3.73 Million - $4.68 Million
60,000 Added 26.09%
290,000 $18.3 Million
Q2 2020

Jul 16, 2020

BUY
$72.34 - $84.0 $16.6 Million - $19.3 Million
230,000 New
230,000 $17.7 Million
Q1 2019

Apr 11, 2019

SELL
$62.53 - $70.05 $11.8 Million - $13.2 Million
-188,200 Closed
0 $0
Q4 2018

Feb 05, 2019

SELL
$60.54 - $79.0 $87,601 - $114,313
-1,447 Reduced 0.76%
188,200 $11.8 Million
Q3 2018

Oct 03, 2018

SELL
$71.28 - $78.92 $5.16 Million - $5.71 Million
-72,380 Reduced 27.62%
189,647 $14.6 Million
Q2 2018

Jul 20, 2018

BUY
$64.88 - $75.68 $1.62 Million - $1.89 Million
25,000 Added 10.55%
262,027 $18.6 Million
Q1 2018

Apr 11, 2018

SELL
$72.84 - $88.8 $3.55 Million - $4.33 Million
-48,724 Reduced 17.05%
237,027 $17.9 Million
Q4 2017

Jan 19, 2018

BUY
$71.15 - $83.52 $9.26 Million - $10.9 Million
130,200 Added 83.7%
285,751 $20.5 Million
Q3 2017

Oct 13, 2017

BUY
$72.11 - $85.47 $11.2 Million - $13.3 Million
155,551
155,551 $12.6 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.